BiotechTube
BioAxone Biosciences

BioAxone Biosciences

Cambridge, United States· Est.
bioaxonebio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $300K

Overview

BioAxone BioSciences is a private, clinical-stage biotech company pioneering treatments for severe neurological conditions, specifically spinal cord injury and cerebral cavernous malformation. The company's technology platform centers on modulating the Rho signaling pathway, a key regulator of neuronal repair and blood-brain barrier integrity. Led by a seasoned management team with strong academic and industry backgrounds, BioAxone is advancing neuroprotective and regenerative therapies in areas with no current pharmacological options. The company operates in high-need, niche markets with potential for significant impact and premium pricing.

NeurologyNeurovascular

Technology Platform

Modulation of the Rho signaling pathway to promote axon regeneration, neuroprotection, and blood-brain barrier integrity.

Funding History

2
Total raised:$300K
Grant$300K
SeedUndisclosed

Opportunities

Addressing massive unmet needs in spinal cord injury and cerebral cavernous malformation with first-in-class pharmacological therapies.
Potential for orphan drug designation and premium pricing in niche markets, as well as expansion into broader neurological indications based on the Rho pathway platform.

Risk Factors

High clinical development risk due to the historical difficulty of achieving CNS regeneration and the novel mechanism of action.
Significant financial risk as a pre-revenue private company requiring continuous capital infusion for expensive neurological trials.
Future regulatory and commercialization challenges for pioneering treatments.

Competitive Landscape

In spinal cord injury, competition includes biotech firms exploring stem cell therapies, biomaterial scaffolds, and other neuroregenerative approaches, but no approved drugs exist. In cerebral cavernous malformation, the field is nascent with few clinical-stage pharmacological programs, positioning BioAxone as a potential first-mover.

More companies in United States →